The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The facility will manufacture tablets, capsules, and injections for the oncology segment
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Pharma Solutions operates 10 research and development and/or production sites globally
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
More than 10,000 scientific publications containing EUDRAGIT
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
The Cabinet has approved budgetary support of Rs. 2207.50 crore in the 15th Finance Commission Cycle to run CAPFIMS as a campus of AIIMS, New Delhi.
The company will provide comprehensive response to USFDA for the observations
Subscribe To Our Newsletter & Stay Updated
